Clinical Trial Update: Anti-CD20 in Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 1/2 clinical trial evaluating an anti-CD20 monoclonal antibody in systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anti-CD20 monoclonal antibody

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Lupus Erythematosus, Systemic | Phase 1, Phase 2 | Status: COMPLETED